Health Tech

Curadh, Alpha Fusion Advance Astatine-211 Collaboration

Curadh MTR Inc. and Alpha Fusion, Inc. are set to showcase their progress in radiopharmaceutical development at the 4th Targeted Radiopharmaceuticals Summit US, scheduled later this month in San Diego. The two companies recently announced plans to enter a strategic partnership, which includes forming a joint venture to drive the global advancement of Astatine-211 (At-211)-based radiopharmaceuticals for the treatment of various cancers. Dr. Alison Armour, Chief Medical Officer and Founder of Curadh MTR, will lead a seminar titled Optimizing Clinical Design to Ensure Patient Safety in Radiopharmaceutical Development. Reflecting on her recent presentation at the World Astatine Community Meeting, she noted, “Astatine’s short 7.2-hour half-life provides significant advantages over other radioisotopes, notably reducing radiation exposure for patients, caregivers, and healthcare personnel.” Commenting on the collaboration, Glenn Kazo, CEO of Curadh,…